• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Industry

  • Print
  • Share
  • E-mail

Public Meeting on Sickle Cell Disease Patient-Focused Drug Development

On February 7, 2014, FDA conducted a public meeting on Patient-Focused Drug Development for sickle cell disease. FDA is interested in obtaining patients’ perspectives on the impact of sickle cell disease on daily life as well as the available therapies for sickle cell disease.

Date: February 7, 2014 
Time: 10 a.m. to 4 p.m.
Location:FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)                
Registration:To register for this meeting, visit: https://patientfocusedsicklecell.eventbrite.com.
Registration has been extended and will close on February 3, 2014.

Webcast Recordings

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on April 8, 2014.